Kantonsspital Graubünden
11
2
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
18%
2 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
Role: collaborator
Liquid Biopsy in Germ Cell Tumors
Role: collaborator
Stibium Metallicum Praeparatum 6x Versus Placebo in the Prevention of Paclitaxel-induced Peripheral Neurotoxicity
Role: collaborator
Prevention of Postoperative Urinary Retention With Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty
Role: lead
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Role: collaborator
ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer
Role: collaborator
Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients
Role: lead
The European Palliative Care Cancer Symptom Study (EPCCS)
Role: collaborator
Hartmann's Versus Primary Anastomosis in Left-sided Colon Perforation
Role: collaborator
Effect of Passive Smoking on Platelet Function and Endothelial Function
Role: lead
Platelet Inhibition by Aspirin, Acetaminophen and NSAID
Role: lead
All 11 trials loaded